Delivery Order SPE2DB22D3501-SPE2DB25FWX99
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,221.54 to AmerisourceBergen Drug Corp for the supply of Xcopri 100 mg tablets (30-count packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 150 mg tablets (30-count units) under a firm fixed price contract valued at $1,393.98. This non-set-aside, competitively awarded delivery order has an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single line item procurement of this neurological...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 22, 2025, for the supply of Xcopri 200 mg tablets in quantities of 30 tablets. The contract, valued at $1,879.85 with a firm fixed price structure, represents a competitive award with no set-aside designation. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 25, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets (30-count units) valued at $3,536.88. This is a firm fixed-price delivery order with no set-aside designation, classified as a competitive award. The contract has an ultimate completion date of August 11, 2025, and performance will be executed at AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,660.38 to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 100 mg on August 11, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $2,070.10. This competitive award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation, indicating it...
- The Defense Logistics Agency awarded a delivery order valued at $1,460.27 to AmerisourceBergen Drug Corp for 30-count tablets of Xcopri 150 mg, a medication primarily used in treating certain seizure disorders. This competitively awarded, firm fixed-price delivery order was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a $2,357.92 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xcopri 25 mg tablets (30-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 6, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contract involves no set-aside designation and identifies Conshohocken, Pennsylvania, as the place of performance,...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWX99Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,652.69 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 200 mg tablets, with performance completion targeted for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order derives from AmerisourceBergen's comprehensive $999,999,999.00 Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which runs through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. The contract enables supply of a broad range of pharmaceutical products and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. Xcopri (cenobamate) is a seizure medication used in neurological treatment protocols, reflecting the vendor's extensive portfolio spanning specialty medications, brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains for federal military and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/19/25 |